ICU患者肺炎克雷伯菌血流感染的特点、新型诊断及治疗方案研究进展

doi:10.3760/cma.j.issn.1007-1245.2024.04.012

摘要/Abstract

摘要：

肺炎克雷伯菌（Kp）在重症监护室（ICU）中引起的血流感染（BSI）近年来因发病率和病死率的惊人上升而引起人们的关注。随着患者的增加以及大量研究的开展，目前临床上对ICU内Kp-BSI的特点有了更加深入的探究，而且宏基因组二代测序技术、微滴式数字PCR以及机器学习等新型病原学诊断技术的发展，为ICU内Kp-BSI病原学诊断开辟了新的视野。同时，新型抗生素的研发以及多种治疗措施的改进和实施有望降低ICU内Kp-BSI患者的病死率。故本文就ICU-Kp-BSI的发生特点、新型的诊断和治疗手段进行综述，并对今后研究方向进行展望，旨在为临床诊治ICU-Kp-BSI提供新思路。

关键词:

肺炎克雷伯菌, 血流感染, 医院获得性, 重症监护室, 进展

Abstract:

In recent years, bloodstream infection (BSI) caused by Klebsiella pneumoniae (Kp) in intensive care unit (ICU) has attracted attention in recent years due to an alarming rise in morbidity and mortality. With the increasing number of Kp-BSI patients and the development of studies, the characteristics of Kp-BSI in ICU have been further explored in clinical practice. Moreover, with the development of metagenomic Next Generation Sequencing technology, droplet digital PCR, machine learning, and other novel etiological diagnostic technologies, a new horizon has been opened for the etiological diagnosis of Kp-BSI in ICU. At the same time, the development of new antibiotics and the improvement of various therapeutic measures are expected to reduce the mortality of Kp-BSI patients in ICU. This article reviews the occurrence characteristics of ICU-Kp-BSI, its new diagnosis and treatment methods, and looks forward to the future research direction, so that we can provide some new ideas for clinical diagnosis and treatment of ICU-Kp-BSI in the future.

Key words:

Klebsiella pneumoniae, Bloodstream infection, Hospital-acquired, Intensive care unit, Progress

陈秋宇刘享田叶莉萍田行瀚.

ICU患者肺炎克雷伯菌血流感染的特点、新型诊断及治疗方案研究进展 [J]. 国际医药卫生导报, 2024, 30(4): 581-585.

Chen Qiuyu, Liu Xiangtian, Ye Liping, Tian Xinghan.

Research progress on the characteristics and new diagnostic and treatment strategies of Klebsiella pneumoniae bloodstream infection in ICU patients [J]. International Medicine and Health Guidance News, 2024, 30(4): 581-585.

参考文献

[1] Cassini A, Plachouras D, Eckmanns T, et al. Burden of six healthcare-associated infections on European population health: estimating incidence-based disability-adjusted life years through a population prevalence-based modelling study[J]. PLoS Med, 2016, 13(10):e1002150. DOI: 10.1371/journal.pmed.1002150.
[2] Tabah A, Buetti N, Staiquly Q, et al. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study[J]. Intensive Care Med, 2023, 49(2):178-190. DOI: 10.1007/s00134-022-06944-2.
[3] Geng S, Mei Q, Zhu C, et al. Metagenomic next-generation sequencing technology for detection of pathogens in blood of critically ill patients[J]. Int J Infect Dis, 2021, 103:81-87. DOI: 10.1016/j.ijid.2020.11.166.
[4] Liu W, Wang C, Pan F, et al. Clinical application of a multiplex droplet digital PCR in the rapid diagnosis of children with suspected bloodstream infections[J]. Pathogens, 2023, 12(5):719. DOI: 10.3390/pathogens12050719.
[5] Chen Y, Ying S, Jiang L, et al. A novel nomogram for predicting risk factors and outcomes in bloodstream infections caused by Klebsiella pneumoniae[J]. Infect Drug Resist, 2022, 15:1317-1328. DOI: 10.2147/IDR.S349236.
[6] Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms[J]. Antimicrob Agents Chemother, 2017, 61(2):e01964-16. DOI: 10.1128/AAC.01964-16.
[7] Chi X, Meng X, Xiong L, et al. Small wards in the ICU: a favorable measure for controlling the transmission of carbapenem-resistant Klebsiella pneumoniae[J]. Intensive Care Med, 2022, 48(11):1573-1581. DOI: 10.1007/s00134-022-06881-0.
[8] Tian L, Tan R, Chen Y, et al. Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality[J]. Antimicrob Resist Infect Control, 2016, 5:48. DOI: 10.1186/s13756-016-0145-0.
[9] 齐臻.ICU肺炎克雷伯菌血流感染的特点及其影响因素分析[D]. 苏州:苏州大学,2022.
[10] 张莉,周芳,茅一萍,等.徐州地区综合ICU导尿管相关尿路感染基线数据调查分析[J].中华医院感染学杂志,2017,27(18):4151-4153,4170. DOI:10.11816/cn.ni.2017- 172548.
[11] Choi MH, Kim D, Park Y, et al. Impact of urinary tract infection-causative microorganisms on the progression to bloodstream infection: a propensity score-matched analysis[J]. J Infect, 2022, 85(5):513-518. DOI: 10.1016/j.jinf.2022.08.039.
[12] De Angelis G, Fiori B, Menchinelli G, et al. Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007-2015) [J]. Eur J Clin Microbiol Infect Dis, 2018, 37(9):1627-1636. DOI: 10.1007/s10096-018-3292-9.
[13] Xiao S, Chen T, Wang H, et al. Drug susceptibility and molecular epidemiology of Klebsiella pneumoniae bloodstream infection in ICU patients in Shanghai, China[J]. Front Med (Lausanne), 2021, 8:754944. DOI: 10.3389/fmed.2021.754944.
[14] 麦东媚,钟嘉城,谭俊青.1 852株肺炎克雷伯菌的临床分布和耐药及感染影响因素研究[J].国际医药卫生导报,2023,29(15):2110-2116. DOI:10.3760/cma.j.issn.1007-1245. 2023.15.009.
[15] Lin YT, Su CF, Chuang C, et al. Appropriate treatment for bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae and Escherichia coli: a nationwide multicenter study in Taiwan[J]. Open Forum Infect Dis, 2018, 6(2):ofy336. DOI: 10.1093/ofid/ofy336.
[16] Vardakas KZ, Matthaiou DK, Falagas ME, et al. Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit[J]. J Infect, 2015, 70(6):592-599. DOI: 10.1016/j.jinf.2014.11.003.
[17] Sawatwong P, Sapchookul P, Whistler T, et al. High burden of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in older adults: a seven-year study in two rural Thai provinces[J]. Am J Trop Med Hyg, 2019, 100(4):943-951. DOI: 10.4269/ajtmh.18-0394.
[18] 祁晶晶,杨雨阳,马秀敏,等.ICU血流感染患者碳青霉烯类抗菌药物耐药肺炎克雷伯菌的毒力和耐药基因分布及其与感染严重程度的相关性[J].医学综述,2022,28(9):1819-1824. DOI:10.3969/j.issn.1006-2084.2022.09.027.
[19] Shao C, Jin Y, Wang W, et al. An outbreak of carbapenem-resistant Klebsiella pneumoniae of K57 capsular serotype in an emergency intensive care unit of a teaching hospital in China[J]. Front Public Health, 2021, 9:724212. DOI: 10.3389/fpubh.2021.724212.
[20] Tang M, Li J, Liu Z, et al. Clonal transmission of polymyxin B-resistant hypervirulent Klebsiella pneumoniae isolates coharboring blaNDM-1 and blaKPC-2 in a tertiary hospital in China[J]. BMC Microbiol, 2023, 23(1):64. DOI: 10.1186/s12866-023-02808-x.
[21] Blauwkamp TA, Thair S, Rosen MJ, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease[J]. Nat Microbiol, 2019, 4(4):663-674. DOI: 10.1038/s41564-018-0349-6.
[22] Liu J, Xu Z, Li H, et al. Metagenomic approaches reveal strain profiling and genotyping of Klebsiella pneumoniae from hospitalized patients in China[J]. Microbiol Spectr, 2022, 10(2):e0219021. DOI: 10.1128/spectrum. 02190-21.
[23] 上海市微生物学会临床微生物学专业委员会,上海市医学会检验医学专科分会,上海市医学会危重病专科分会.血流感染临床检验路径专家共识[J].中华传染病杂志,2022,40(8):457-475. DOI:10.3760/cma.j.cn311365-20220130- 00033.
[24] Zheng Y, Jin J, Shao Z, et al. Development and clinical validation of a droplet digital PCR assay for detecting Acinetobacter baumannii and Klebsiella pneumoniae in patients with suspected bloodstream infections[J]. Microbiologyopen, 2021, 10(6):e1247. DOI: 10.1002/mbo3.1247.
[25] Lin K, Zhang HC, Zhao YH, et al. The direct application of plasma droplet digital PCR in the ultra-early pathogen detection and warning during sepsis: Case reports[J]. J Infect Public Health, 2022, 15(4):450-454. DOI: 10.1016/j.jiph.2022.03.008.
[26] Liu W, Ying N, Mo Q, et al. Machine learning for identifying resistance features of Klebsiella pneumoniae using whole-genome sequence single nucleotide polymorphisms[J]. J Med Microbiol, 2021, 70(11). DOI: 10.1099/jmm.0.001474.
[27] Wang C, Wang Z, Wang HY, et al. Large-scale samples based rapid detection of ciprofloxacin resistance in Klebsiella pneumoniae using machine learning methods[J]. Front Microbiol, 2022, 13:827451. DOI: 10.3389/fmicb.2022.827451.
[28] Wang X, Wang Q, Cao B, et al. Retrospective observational study from a Chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant enterobacteriaceae bacteremia[J]. Antimicrob Agents Chemother, 2018, 63(1):e01511- e01518. DOI: 10.1128/AAC.01511-18.
[29] Justo JA, Bookstaver PB, Kohn J, et al. Combination therapy vs. monotherapy for Gram-negative bloodstream infection: matching by predicted prognosis[J]. Int J Antimicrob Agents, 2018, 51(3):488-492. DOI: 10.1016/j.ijantimicag.2017.09.007.
[30] Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study[J]. Lancet Infect Dis, 2017, 17(7):726-734. DOI: 10.1016/S1473- 3099(17)30228-1.
[31] Zhang S, Yang Z, Sun L, et al. Clinical observation and prognostic analysis of patients with Klebsiella pneumoniae bloodstream infection[J]. Front Cell Infect Microbiol, 2020, 10:577244. DOI: 10.3389/fcimb.2020. 577244.
[32] 黄丽萍,林嘉萍,余雪莹,等.114例成人肺炎克雷伯菌血流感染的临床特征及预后[J].中国感染与化疗杂志,2022,22(6):680-687. DOI:10.16718/j.1009-7708.2022.06.005.
[33] Medeiros GS, Rigatto MH, Falci DR, et al. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection[J]. Int J Antimicrob Agents, 2019, 53(2):152-157. DOI: 10.1016/j.ijantimicag.2018.10.010.
[34] Fang Y, Zhong Q, Chen Y, et al. Ceftazidime/avibactam, polymyxin or tigecycline as a rescue strategy for the treatment of carbapenem-resistant Klebsiella pneumoniae in bloodstream infection: a retrospective cohort study[J]. Infect Drug Resist, 2023, 16:2963-2971. DOI: 10.2147/IDR.S409506.
[35] Kong W, Yang X, Shu Y, et al. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection[J]. Front Public Health, 2023, 11:1118307. DOI: 10.3389/fpubh.2023.1118307.
[36] Tsolaki V, Mantzarlis K, Mpakalis A, et al. Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients[J]. Antimicrob Agents Chemother, 2020, 64(3):e02320-19. DOI: 10.1128/AAC.02320-19.
[37] Karaiskos I, Daikos GL, Gkoufa A, et al. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study[J]. J Antimicrob Chemother, 2021, 76(3):775-783. DOI: 10.1093/jac/dkaa503.
[38] Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial[J]. Lancet Infect Dis, 2021, 21(2):226-240. DOI: 10.1016/S1473-3099(20)30796-9.
[39] Yu W, Luo Q, Shen P, et al. New options for bloodstream infections caused by colistin- or ceftazidime/avibactam-resistant Klebsiella pneumoniae[J]. Int J Antimicrob Agents, 2021, 58(6):106458. DOI: 10.1016/j.ijantimicag.2021.106458.
[40] Waldmann H. Human monoclonal antibodies: the benefits of humanization[J]. Methods Mol Biol, 2019, 1904:1-10. DOI: 10.1007/978-1-4939-8958-4_1.
[41] Dhungana G, Regmi M, Paudel P, et al. Therapeutic efficacy of bacteriophage therapy to treat carbapenem resistant Klebsiella pneumoniae in mouse model[J]. J Nepal Health Res Counc, 2021, 19(1):76-82. DOI: 10.33314/jnhrc.v19i1.3282.
[42] Yadegar A, Pakpoor S, Ibrahim FF, et al. Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection[J]. Cell Host Microbe, 2023, 31(5):695-711. DOI: 10.1016/j.chom.2023.03.019.